Edwards Lifesciences (EW) Net Cash Flow (2009 - 2026)

Edwards Lifesciences' Net Cash Flow history runs 18 years deep, the most recent figure standing at -$500.2 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 564.44% year-over-year to -$500.2 million in Q1 2026; TTM through Mar 2026 was -$682.4 million, a 135.75% decrease from a year earlier, with the FY2025 full-year figure at -$74.5 million, down 103.98% from the prior year.
• Net Cash Flow fell to -$500.2 million in Q1 2026 per EW's latest filing, from $241.2 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $2.1 billion in Q3 2024 and bottomed at -$675.6 million in Q4 2024.
• The 5-year median for Net Cash Flow is $108.0 million (2023), against an average of $90.7 million.
• Across the five-year window, Net Cash Flow surged 827.79% in 2023 and sank 564.44% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at -$460.9 million in 2022, then jumped by 43.05% to -$262.5 million in 2023, then sank by 157.37% to -$675.6 million in 2024, then surged by 135.7% to $241.2 million in 2025, then slumped by 307.38% to -$500.2 million in 2026.
• Per Business Quant, the three latest EW Net Cash Flow figures stand at -$500.2 million (Q1 2026), $241.2 million (Q4 2025), and -$594.2 million (Q3 2025).